Comparing Inlyta vs Votrient
| Inlyta (axitinib) | Votrient (pazopanib) |
|
|---|
| Inlyta (axitinib) | Votrient (pazopanib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Renal Cell Carcinoma. Inlyta may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Soft Tissue Sarcoma, Renal Cell Carcinoma. Votrient may also be used for purposes not listed in this medication guide. |
Related suggestions Popular comparisons
|
|||||||||||||||
| More about Inlyta (axitinib) | More about Votrient (pazopanib) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Inlyta has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Votrient has an average rating of 8.0 out of 10 from a total of 82 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 9% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Inlyta side effects |
View all Votrient side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Inlyta prices |
View all Votrient prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
6.1 hours |
30.9 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 251 drugs are known to interact with Inlyta:
|
A total of 706 drugs are known to interact with Votrient:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
January 27, 2012 |
October 19, 2009 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Lenvima
Lenvima (lenvatinib) is used to treat thyroid cancer, advanced renal cell carcinoma, hepatocellular ...
Cabometyx
Cabometyx is used to treat advanced kidney cancer, liver cancer, thyroid cancer, and pancreatic and ...
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Lenvatinib
Lenvatinib is used to treat thyroid cancer, kidney cancer, liver cancer, and advanced endometrial ...
Everolimus
Everolimus (Afinitor, Afinitor Disperz, Zortress) belongs to a class of drugs called kinase ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.